Page 7 of 10: studies 61 to 70 of 95, newest first. Back to the MDMA for anxiety overview
Expert Review of Clinical Pharmacology December 17, 2017 Alexander M. Sherwood, Thomas E Prisinzano
Disrupted mental health affects up to one in three individuals globally and is an unmet medical challenge contributing to individual suffering as well as significant societal and economic burden [1...
Trends in Psychiatry and Psychotherapy November 11, 2017 Lysa Remy, Juliana Nichterwitz Scherer, Luciano Santos Pinto Guimarães et al. 12 citations
Abstract Background This study examined drug use patterns and psychiatric symptoms of anxiety and depression among young Brazilian sexual minority ecstasy and LSD users and compared findings with those reported for their heterosexual peers. Method This cross-sectional study employed targeted sampling and ethnographic mapping approaches via face-to-face interviews conducted at bars and...
Psychopharmacology July 1, 2017 Anya K. Bershad, Melissa A. Miller, Harriet de Wit 12 citations
Rationale ±3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) is a stimulant-psychedelic drug with unique social effects. It may dampen reactivity to negative social stimuli such as social threat and rejection. Perhaps because of these effects, MDMA has shown promise as a treatment for post-traumatic stress disorder (PTSD). However, the effect of single doses of MDMA on responses to an acute...
Fortschritte der Neurologie · Psychiatrie July 1, 2017 Tomislav Majić, Henrik Jungaberle, Timo Torsten Schmidt et al. 10 citations
Zusammenfassung Hintergrund Der Einsatz von serotonergen Halluzinogenen (Psychedelika) wie Lysergsäure-Diethylamid (LSD) und Psilocybin und Entaktogenen wie 3,4-Methylendioxymethamphetamin (MDMA) im Rahmen von Psychotherapie ist in den letzten Jahren wieder zunehmend ins Licht des wissenschaftlichen Interesses gerückt. Die vorliegende Arbeit fasst die aktuelle Evidenz zur substanzunterstützten...
Pharmacological Reports April 2017 Barbara Budzynska, Agnieszka Michalak, Małgorzata Frankowska et al.
Abuse of more than one psychoactive drug is becoming a global problem. Our experiments were designed to examine the effects of a concomitant administration of 3,4-methylenedioxy-methamphetamine (MDMA) and mephedrone on depression- and anxiety-like behaviors and cognitive processes in Swiss mice. In order to investigate the drug interactions the forced swimming test (FST) - an animal model of...
Neurotoxicology December 2016 Courtney L Huff, Rachel L Morano, James P Herman et al.
3,4-Methylenedioxy-methamphetamine (MDMA) is a unique psychostimulant that continues to be a popular drug of abuse. It has been well documented that MDMA reduces markers of 5-HT axon terminals in rodents, as well as humans. A loss of parvalbumin-immunoreactive (IR) interneurons in the hippocampus following MDMA treatment has only been documented recently. In the present study, we tested the...
Experimental and Clinical Psychopharmacology August 1, 2016 Albert Garcia‐romeu, Brennan Kersgaard, Peter H. Addy 198 citations
Hallucinogens fall into several different classes, as broadly defined by pharmacological mechanism of action, and chemical structure. These include psychedelics, entactogens, dissociatives, and other atypical hallucinogens. Although these classes do not share a common primary mechanism of action, they do exhibit important similarities in their ability to occasion temporary but profound...
Journal of Psychopharmacology April 2016 Matthew J. Baggott, Jeremy Coyle, Jennifer D. Siegrist et al.
The drug 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy", "molly") is a widely used illicit drug and experimental adjunct to psychotherapy. MDMA has unusual, poorly understood socioemotional effects, including feelings of interpersonal closeness and sociability. To better understand these effects, we conducted a small (n=12) within-subjects double-blind placebo controlled study of the...
Progress in Neuro-Psychopharmacology and Biological Psychiatry January 4, 2016 Alicia Danforth, Christopher M Struble, Berra Yazar-Klosinski et al. 110 citations
The first study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of social anxiety in autistic adults commenced in the spring of 2014. The search for psychotherapeutic options for autistic individuals is imperative considering the lack of effective conventional treatments for mental health diagnoses that are common in this population. Serious Adverse Events (SAEs)...
Translational Psychiatry September 15, 2015 Matthew B Young, Raül Andero, Kerry J. Ressler et al. 137 citations
Abstract Acutely administered 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) has been proposed to have long-term positive effects on post-traumatic stress disorder (PTSD) symptoms when combined with psychotherapy. No preclinical data support a mechanistic basis for these claims. Given the persistent nature of psychotherapeutic gains facilitated by MDMA, we hypothesized that MDMA improves...